Genetic polymorphism of S-mephenytoin 4'-hydroxylation

Psychopharmacology Bulletin

Volumn 32, Issue 2, 1996, Pages 219-230

  Daniel, Harold I ^b   Edeki, Timi I ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

CYP2C19; genetic; hydroxylation; mephenytoin; polymorphism

Indexed keywords

AMITRIPTYLINE; CHLORPROGUANIL; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 ISOENZYME; DIAZEPAM; HEXOBARBITAL; IMIPRAMINE; MEPHENYTOIN; METHYLPHENOBARBITAL; MOCLOBEMIDE; NORDAZEPAM; NORMEPHENYTOIN; OMEPRAZOLE; PHENYTOIN; PROPRANOLOL;

ARTICLE; CONVULSION; DRUG DISTRIBUTION; DRUG METABOLISM; ENANTIOMER; ETHNIC GROUP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYDROXYLATION; PRIORITY JOURNAL;

ETHNIC GROUPS; HUMANS; HYDROXYLATION; MEPHENYTOIN; POLYMORPHISM, GENETIC; PREVALENCE;

EID: 0029783939     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Abbott, JA, and Schwab, RS. Mesantoin in the treatment of epilepsy: A study of its effect on the leucocyte count in seventy-nine cases. N. Engl. J. Med. 250:197-199, 1954.
2. Adedoyin, A; Arns, P; Richards, W; Wilkinson, GR; and Branch, RA. Differential effect of cirrhosis on metabolism due to P450 2D6 and P450 2Cmp (Abstract #121). Pharmacologist 35:176, 1993.
3. Adedoyin, A; Prakash, C; O'Shea, D; Blair, IA; and Wilkinson, GR. Stereoselective disposition of hexobarbital and its metabolites: Relationship to the S-mephenytoin polymorphisms in Caucasian and Chinese subjects. Pharmacogenetics 4:27-38, 1994.
4. Andersson, T; Miners, JO; Veronese, ME; and Birkett, DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 37:597-606, 1994.
5. Andersson, T; Regardh, CG; Lou, Y-C; Zhang, Y; Dahl, ML; and Bertilsson, L. Polymorphic hydroxylation of S-mephenytoin and omeprazole in Caucasian and Chinese subjects. Pharmacogenetics 2:25-31, 1992.
6. Atiba, JO; Blaschke, TF; and Wilkinson, GR. Effects of ketoconazole on the polymorphic 4′-hydroxylation of S-mephenytoin and debrisoquine. Br. J. Clin. Pharmacol. 28:161-165, 1989.
7. Balian, JD; Sukhova, N; Harris, JW; Hewett, J; Pickle, L; Goldstein, JA; Woosley, RL; and Flockhart, DA. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin. Pharmacol. Ther. 57:662-669, 1995.
8. Baumann, P, and Jonzier-Percy, M. GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin. Clin. Chem. Acta 171:211-222, 1988.
9. Bertilsson, L; Henthorn, TK; Sanz, E; Tybring, G; Sawe, J; and Villen, T. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquine hydroxylation phenotype. Clin. Pharmacol. Ther. 45:348-355, 1989.
10. Bertilsson, L; Lou, Y-C; Du, YL; Liu, Y; Kuang, TY; Liao, XM; Wang, KY; Reviriego, J; Iselius, L; and Sjöqvist, F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin. Pharmacol. Ther. 51: 388-397, 1992.
11. Breimer, DD; Zilly, W; and Richter, E. Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery. Clin. Pharmacol. Ther. 18:433-440, 1975.
12. Breyer-Pfaff, U; Pfandl, B; Nill, K; Nusser, E; Monney, C; Jonzier-Percy, M; Baettig, D; and Baumann, P. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin. Pharmacol. Ther. 52:350-358, 1992.
13. Brosen, K; Skjelbo, E; and Flachs, H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br. J. Clin. Pharmacol. 36:105-108, 1993.
14. Butler, TC. Metabolic demethylation of 3-methyl-5-ethyl-5-phenylhydantoin (Mesantoin). J. Pharmacol. Exp. Ther. 104:299-308, 1952.
15. Butler, TC. Quantitative studies of the physiological disposition of 3-methyl-5-ethyl-5-phenylhydantoin (Mesantoin) and 5-ethyl-5-phenylhydantoin (Nirvanol). J. Pharmacol. Exp. Ther. 109:340-345, 1953.
16. Butler, TC, and Waddel, WJ. A pharmacological comparison of the optical isomer of 5-ethyl-5-phenylhydantoin (Nirvanol) and of 3-methyl-5-ethyl-5-phenylhydantoin (Mesantoin). J. Pharmacol. Exp. Ther. 110:120-125, 1954.
17. Daly, AK; Cholerton, S; Gregory, W; and Idle, JR. Metabolic polymorphisms. Pharmacol. Ther. 57:129-160, 1993.
18. de Morais, SMF; Goldstein, JA; Xie, HG; Huang, SL; Lu, YQ; Xia, H; Xiao, ZS; Ile, N; and Zhou, HH. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin. Pharmacol. Ther. 58:404-411, 1995.
19. de Morais, SM; Wilkinson, GR; Blaisdell, KN; Meyer, UA; and Goldstein, JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269 (22): 15419-15422, 1994a.
20. de Morais, SM; Wilkinson, GR; Blaisdell, KN; Meyer, UA; and Goldstein, JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46:594-598, 1994b.
21. Doshi, BS; Kulkami, RD; Chauhan, BL; and Wilkinson, GR. Frequency of impaired mephenytoin 4′-hydroxylation in an Indian population. Br. J. Clin. Pharmacol. 30:779-780, 1990.
22. Drohse, A; Bathum, L; Brosen, K; and Gram, LF. Mephenytoin and sparteine oxidation: Genetic polymorphisms in Denmark. Br. J. Clin. Pharmacol. 27:620-625, 1989.
23. Eadie, MJ; Bochner, F; Hooper, WD; and Tyrer, JH. Preliminary observations on the pharmacokinetics of methylphenobarbitone. Clin. Exp. Neurol. 15:131-144, 1978.
24. Edeki, TI, and Brase, DA. Phenytoin disposition and toxicity: Role of pharmacogenetic and interethnic factors. Drug Metab. Reviews 27(3):449-469, 1995.
25. Edeki, TI; Goldstein, JA; de Morais, SMF; Hajiloo, L; Butler, M; Chapdelaine, P; and Wilkinson, GR. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African Americans. Pharmacogenetics, in press 1996.
26. Fritz, S; Linden, W; Roots, I; Frey, BM; and Kupfer, A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J. Pharmacol. Exp. Ther. 241:615-622, 1987.
27. Furuya, H; Meyer, UA; Gelboin, HV; and Gonzalez, FJ. Polymerase chain reaction-directed identification, cloning and quantification of human CYP2C18 mRNA. Mol. Pharmacol. 40:375-382, 1991.
28. Goldstein, JA; Faletto, MB; Ronkes-Sparks M; Sullivan, T; Kitareewan, S; Rancy, JL; Lasker, JM; and Ghanayem, BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry, 33:1743-1752, 1994.
29. Gram, LF; Guentert, TW; Grange, S; Vistisen, K; and Brosen, K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study. Clin. Pharmacol. Ther. 57:670-677, 1995.
30. Greenblatt, DJ; Allen, MD; Harmatz, JS; and Shader, RI. Diazepam disposition determinants. Clin. Pharmacol. Ther. 27:301-312, 1980.
31. Heim, MH, and Meyer, UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 14:49-58, 1992.
32. Helsby, NA; Ward, SA; Howells, RE; and Breckenridge, AM. In vitro metabolism of the biguanide antimalarials in human liver microsomes: Evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br. J. Clin. Pharmacol. 30:287-291, 1990.
33. Horai, Y; Nakano, M; Ishizaki, T; Ishikawa, K; Zhou, HH; Zhou, BJ; Liao, CL; and Zhang, LM. Metoprolol and mephenytoin oxidation polymorphisms in Far East Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 46:198-207, 1989.
34. Inaba, T. Genetic polymorphism of mephenytoin. In: Kalow W; Goedde, HW; and Agarwal, DP, eds. Ethnic Differences in Reactions To Drugs and Xenobiotics. New York: Alan R Liss, 1986. pp. 139-156.
35. Inaba, T; Jorge, LF; and Arias, TD. Mephenytoin hydroxylation in the Cuna Amerindians of Panama. Br. J. Clin. Pharmacol. 25:75-79, 1988.
36. Inaba, T; Jurima, M; Nakano, M; and Kalow, W. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clin. Pharmacol. Ther. 30:670-676, 1984.
37. Inaba, T; Jurima, M; and Kalow, W. Family studies of mephenytoin hydroxylation deficiency. Am. J. Hum. Genet. 38:768-772, 1986.
38. Ingelman-Sunberg, M; Johansson, I; Persson, I; Yue, Q-Y; Dahl, ML; Bertilsson, L; and Sjöqvist, F. Genetic polymorphisms of cytochromes P450: Interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 2:264-271, 1992.
39. Iyun, AO; Tucker, GT; Woods, HF; and Lennard, MS. The 4′-hydroxylation of (S)-mephenytoin in Nigerians: A population study. In: Ingelman-Sundberg, M; Gustafsson, JA; and Orrenius, S, eds. Eighth International Symposium: Microsomes and Drug Oxidations. Stockholm: Karolinska Institutet, 1990.
40. Jacqz, E; Dulac, H; and Mathieu, H. Phenotyping polymorphic drug metabolism in French Caucasian population. Eur. J. Clin. Pharmacol. 35:167-171, 1988.
41. Jacqz, E; Hall, SD; Branch, RA; and Wilkinson, GR. Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co-regulated substrate, mephobarbitol. Clin. Pharmacol. Ther. 39:646-653, 1986.
42. Jurima, M; Inaba, T; Kadar, D; and Kalow, W. Genetic polymorphism of mephenytoin p-(4′) hydroxylation: Differences between Orientals and Caucasians. Br. J. Clin. Pharmacol. 19:483-487, 1985.
43. Kaisary, A; Smith, P; Jacqz, E; McAllister, CB; Wilkinson, GR; Ray, WA; and Branch, RA. Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res. 47:5488-5493, 1987.
44. Kalow, W. The genetic defect of mephenytoin hydroxylation. Xenobiotica 16:379-389, 1986.
45. Kiivet, RA; Svensson, JO; Bertilsson, L; and Sjöqvist, F. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians. Pharmacol. Toxicol. 72:113-115, 1993.
46. 14C] mephenytoin in the dog. J. Pharmacol. Exp. Ther. 209:190-195, 1979.
47. Kupfer, A; Bircher, J; and Preisig, R. Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethylhydantoin (Nirvanol) in the dog. J. Pharmacol. Exp. Ther. 203:493-499, 1977.
48. Kupfer, A, and Branch, RA. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin. Pharmacol. Ther. 38:414-418, 1985.
49. Kupfer, A; Desmond, P; Patwardham, R; Schenker, S; and Branch, RA. Mephenytoin hydroxylation deficiency: Kinetics after repeated doses. Clin. Pharmacol. Ther. 35:33-39, 1984a.
50. Kupfer, A; Desmond, P; Schenker, S; and Branch, RA. Family study of a genetically determined deficiency of mephenytoin hydroxylation in man. Pharmacologist 21:173, 1979.
51. Kupfer, A; Desmond, P; Schenker, S; and Branch, RA. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J. Pharmacol. Exp. Ther. 221:590-597, 1982.
52. Kupfer, A; Dick, B; and Preisig, R. Polymorphic mephenytoin hydroxylation in man: A new phenotype in the genetic control of hepatic drug metabolism. Hepatology 81:34, 1981b.
53. Kupfer, A; Lawson, J; and Branch, RA. Stereoselectivity of the arene epoxide pathway of mephenytoin hydroxylation in man. Epilepsia 25:1-7, 1984b.
54. Kupfer, A; Patwardham, R; Ward, S; Schenker, S; Preisig, R; and Branch, RA. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans. J. Pharmacol. Exp. Ther. 230:28-33, 1984.
55. Kupfer, A, and Preisig, R. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26:753-759, 1984c.
56. Kupfer, A; Roberts, RK; Schenker, S; and Branch, RA. Stereoselective metabolism of mephenytoin in man. J. Pharmacol. Exp. Ther. 218:193-199, 1981a.
57. Kupferberg, HJ. Mephenytoin and ethotoin. In: Woodbury, DM; Penny, JK; and Peppenger, CE, eds. Antiepileptic Drugs. New York: Raven Press, 1982. pp. 283-295.
58. Llerena, A; Herraiz, AG; Cobaleda, J; Johansson, I; and Dahl, ML. Debrisoquine and mephenytoin hydroxylation phenotypes and CYP 2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin. Pharmacol. Ther. 54:606-611, 1993a.
59. Llerena, LA; Valdivielso, MJ; Benitez, J; and Bertilsson, L. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes. Pharmacol. Toxicol. 73:46-48, 1993b.
60. Lower, GM; Nielsson, T; Nelson, CE; Wolf, H; Gamsky, TE; and Bryan, GT. N-Acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect. 29:71-79, 1979.
61. Masimirembwa, C; Bertilsson, L; Johansson, I; Hasler, JA; and Ingelman-Sundberg, M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin. Pharmacol. Ther. 57:656-661, 1995.
62. May, DG; Porter, J; Wilkinson, GR; and Branch, RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P450 3A4 activity, in a white population. Clin. Pharmacol. Ther. 55:492-500, 1994.
63. Nakamura, K; Goto, F; Ray, WA; McAllister, CB; Jacqz, E; and Wilkinson GR. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38:402-408, 1985.
64. Nielsen, KK; Brosen, K; Hansen, MGJ; and Gram, LF. Single-dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidative polymorphisms. Clin. Pharmacol. Ther. 55:518-527, 1994.
65. Pollock, BG; Perel, JM; Kirshner, M; Altieri, LP; Yeager, AL; and Reynolds, CF. S-mephenytoin 4′-hydroxylation in older Americans. Eur. J. Clin. Pharmacol. 40:609-611, 1991.
66. Price-Evans, DA; Krahn, P; and Narayanan, N. The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphism in Saudi Arabians and Filipinos. Pharmacogenetics 5:64-71, 1995.
67. Relling, MV; Aoyama, T; Gonzalez, FJ; and Meyer, UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252:442-447, 1990.
68. Reviriego, J; Bertilsson, L; Carrillo, JA; Llerena, A; Valdivielso, MJ; and Benitez, J. Frequency of S-mephenytoin deficiency in 373 Spanish subjects compared to other Caucasian populations. Eur. J. Clin. Pharmacol. 44:593-595, 1993.
69. Romkes, M; Faletto, MB; Blaisdell, JA; Rancy, JL; and Goldstein, JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30:3247-3255, 1991.
70. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolism of S-mephenytoin. Clin. Pharmacol. Ther. 52:170-180, 1992.
71. Rost, KL, and Roots, I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test. Clin. Pharmacol. Ther. 55:402-411, 1994.
72. Saner, H; Kupfer, A; Dick, B; and Gutner, HP. Pharmackogenetik der Arzneinittelhydroxylierung hei Patienten nit primar vaskulaver pulmonaler Hypertonic (PVPH) nach Einnahme von Aminorex-Fumarat (AF, menocil). Schweiz Med. Wochenschr 112:1634, 1982.
73. Sanz, EJ; Villen, T; Alin, C; and Bertilsson, L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin. Pharmacol. Ther. 45:495-497, 1989.
74. Schellens, JHM; Van der Wart, JHF; and Breimer, DD. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects. Br. J. Clin. Pharmacol. 29:665-671, 1990.
75. Setiabudy, R; Chiba, K; Kusuka, M; and Ishizaki, T. Caution in the use of 100mg of racemic mephenytoin for phenotyping Southeastern Oriental subjects. Br. J. Clin. Pharmacol. 33:665-666, 1992.
76. Setiabudy, R; Kusaka, M; Chiba, K; Darmansjah, I; and Ishizaki, T. Dapsone N-acetylation, metoprolol a-hydroxylation, and S-mephenytoin 4′-hydroxylation polymorphisms in an Indonesian population: A cocktail and extended phenotyping assessment trial. Clin. Pharmacol. Ther. 56:142-153, 1994.
77. Sindrup, SH; Brosen, K; Hansen, MGJ; Aaes-Jorgensen, T; Overo, KF; and Gram, LF. Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphism. Ther. Drug Monit. 15:11-17, 1993.
78. Skjelbo, E; Brosen, K; Hallas, J; and Gram, LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. 49:18-23, 1991.
79. Sohn, DR; Kusaka, M; Ishizaki, T; Shin, SG; and Chiba, K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin. Pharmacol. Ther. 52:160-169, 1992.
80. Srivastava, PK; Yun, CH; Beaume, PH; Ged, C; and Guengerich, FP. Separation of human liver tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol. 40:69-79, 1991.
81. Theodore, WH; Newmark, ME; Desai, BT; Kupferberg, HJ; Penry, JK; Porter, RJ; and Yonekawa WD. Disposition of mephenytoin and its metabolite, nirvanol, in epileptic patients. Neurology 34:1100-1102, 1984.
82. Troupin, AS; Ojemann, LM; and Dodrill, CB. Mephenytoin: A reappraisal. Epilepsia 17:403-414, 1976.
83. Tybring, G, and Bertilsson, L. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 2:241-243, 1992.
84. Ward, SA; Goto, F; Nakamura, K; Jacqz, E; Wilkinson, GR; and Branch, RA. S-mephenytoin hydroxylase is inherited as an autosomal-recessive trait in Japanese families. Clin. Pharmacol. Ther. 42:96-99, 1987.
85. Ward, SA; Walle, T; Walle, UK; Wilkinson, GR; and Branch, RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin. Pharmacol. Ther. 45(1):72-79, 1989.
86. Walle, T; Walle, UK; Cowart, TD; and Conradi, EC. Pathwayselective sex differences in the metabolism of propranolol in human subjects. Clin. Pharmacol. Ther. 46:257-263, 1989.
87. Wedlund, PJ; Aslanian, WS; Jacqz, E; McAllister, CB; Branch, RA; and Wilkinson, GR. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J. Pharmacol. Exp. Ther. 234:662-669, 1985.
88. Wedlund, PJ; Aslanian, WS; McAllister, CB; Wilkinson, GR; and Branch, RA. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther. 36:773-780, 1984.
89. Wedlund, PJ; Sweetman, BJ; Wilkinson, GR; and Branch, RA. Pharmacogenetic association between the formation of 4-OH-mephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab. Dispos. 15:277-279, 1987.
90. Wilkinson, GR; Guengerich, FP; and Branch, RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43:53-76, 1989.
91. Wrighton, SA; Stevens, JC; Becker, GW; and Vanden Branden, M. Isolation and characterization of liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306:240-245, 1993.
92. Yasumori, T; Murayama, N; Yamazoe, Y; and Kato, R. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Clin. Pharmacol. Ther. 47:313-322, 1990.
93. Yasumori, T; Murayama, N; Yamazoe, Y; and Kato, R. Cytochrome P-450 human-2(P-450IIC9) in mephenytoin hydroxylation polymorphism in human livers: Differences in substrate and stereoselectivities among microheterogenous P-450IIC species expressed in yeasts. J. Biochem. 109:711-717, 1991.
94. Yasumori, T; Yamazoe, Y; Abe, A; Nogi, Y; Fukasawa, T; and Kato, R. Expression of a human P-450IIC gene in yeast cells using galactose-inducible expression system. Mol. Pharmacol. 35:443-449, 1989.
95. Zhang, Y; Blouin, RA; McNamara, PJ; Steinmetz, J; and Wedlund, P. Limitation to the use of urinary S-/ R-mephenytoin ratio in pharmacogenetic studies. Br. J. Clin. Pharmacol. 31:350-352, 1991.
96. Zhang, Y; Reviriego, J; Lou, Y; Sjöqvist, F; and Bertilsson, L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: Interethnic differences in comparison with white subjects. Clin. Pharmacol. Ther. 48:496-502, 1990.
97. Zhou, HH; Anthony, LB; Wood, AJJ; and Wilkinson, GR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br. J. Clin. Pharmacol. 30:471-475, 1990.
98. Zilly, W; Breimer, DD; and Richter, E. Hexobarbital disposition in compensated and decompensated cirrhosis of the liver. Clin. Pharmacol. Ther. 23:525-534, 1978.